Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective Study Comparing Anti CD30 (Brentuximab Vedotin) With AVD Versus ABVD Chemotherapy Protocol Frontline Therapy in Patients With Advanced Classical Hodgkin Lymphoma

NCT07171827 is registered in ClinicalTrials.gov with Helwan University as lead sponsor.

NCT NCT07171827
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07171827 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective Study Comparing Anti CD30 (Brentuximab Vedotin) With AVD Versus ABVD Chemotherapy Protocol Frontline Therapy in Patients With Advanced Classical Hodgkin Lymphoma
Lead sponsor
Helwan University
Phase
Not applicable
Overall status
Completed
Start date
March 1, 2023
Completion date
February 1, 2025
Enrollment
60 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced classical hodgkin lymphoma, anti-cd30, brentuximab, dacarbazine, doxorubicin, frontline, vinblastine